Drug Database · Clinicians

Indapamide

Brands (3) Cardiomide, Natrilix SR, Vazamide SRShow all

Thiazide-like Diuretic US FDA class
Antihypertensive (sulfonamide); Diuretic (sulfonamide) PH FDA category

Rx · Prescription drug4 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID deb83f97-6c61-4a09-bed6-18dcf1183405, version date September 12, 2025 (Indapamide · ANI Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Contraindications

CONTRAINDICATIONS Anuria. Known hypersensitivity to indapamide or to other sulfonamide-derived drugs.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Hypertension The adult starting indapamide dose for hypertension is 1.25 mg as a single daily dose taken in the morning. If the response to 1.25 mg is not satisfactory after 4 weeks, the daily dose may be increased to 2.5 mg taken once daily. If the response to 2.5 mg is not satisfactory after 4 weeks, the daily dose may be increased to 5 mg taken once daily, but adding another antihypertensive should be considered.

Edema of Congestive Heart Failure The adult starting indapamide dose for edema of congestive heart failure is 2.5 mg as a single daily dose taken in the morning. If the response to 2.5 mg is not satisfactory after one week, the daily dose may be increased to 5 mg taken once daily. If the antihypertensive response to indapamide is insufficient, indapamide may be combined with other antihypertensive drugs, with careful monitoring of blood pressure.

It is recommended that the usual dose of other agents be reduced by 50% during initial combination therapy. As the blood pressure response becomes evident, further dosage adjustments may be necessary. In general, doses of 5 mg and larger have not appeared to provide additional effects on blood pressure or heart failure, but are associated with a greater degree of hypokalemia.

There is minimal clinical trial experience in patients with doses greater than 5 mg once a day.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness of indapamide in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Clinical studies of indapamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide in elderly females (see WARNINGS).

Dosage forms

Philippines

  • Sustained-release tablet: 1.5 mg
  • Prolonged-release tablet: 1.5 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Indapamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Indapamide
Package insert
CardiomideIndapamide
1.5 mg Sustained-Release tabletAluminum Strip Foil x 10's (Box of 30's)
RxVAT-exempt
Bal Pharma LimitedIndia
Endure Medical Inc.Importer: Singapore Genebio Inc.
DR-XY44349
Mar 23, 2030
Natrilix SRIndapamide
1.5 mg Sustained-Release TabletAlu/Alu Blister Strip x 10's (Box of 30's)
RxVAT-exempt
Les Laboratoires Servier IndustrieFrance
Zuellig Pharma CorporationImporter: Servier Philippines, Inc.
DR-XY21781
Aug 15, 2031
Vazamide SRIndapamide
1.5 mg Sustained-Release TabletPVC/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
TORRENT PHARMACEUTICALS, LTD.India
TORRENT PHARMA PHILIPPINES, INC.
DR-XY32026
Jul 28, 2029
(no brand name)Indapamide
1.5 mg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ind-Swift LimitedIndia
Onesource Pharma Solutions, Inc.
DRP-10950
Dec 22, 2026

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide. This occurred primarily in elderly females. (See PRECAUTIONS, Geriatric Use.) This appears to be dose related. Also, a large case-controlled pharmacoepidemiology study indicates that there is an increased risk of hyponatremia with indapamide 2.5 mg and 5 mg doses.

Hyponatremia considered possibly clinically significant (< 125 mEq/L) has not been observed in clinical trials with the 1.25 mg dosage (see PRECAUTIONS). Thus, patients should be started at the 1.25 mg dose and maintained at the lowest possible dose. (See DOSAGE AND ADMINISTRATION.) Hypokalemia occurs commonly with diuretics (see ADVERSE REACTIONS, Hypokalemia), and electrolyte monitoring is essential, particularly in patients who would be at increased risk from hypokalemia, such as those with cardiac arrhythmias or who are receiving concomitant cardiac glycosides.

In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity. Read prescribing information for lithium preparations before use of such concomitant therapy.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Other Antihypertensives Indapamide may add to or potentiate the action of other antihypertensive drugs. In limited controlled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy.

Lithium See WARNINGS. Post-Sympathectomy Patient The antihypertensive effect of the drug may be enhanced in the post-sympathectomized patient. Norepinephrine Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Most adverse effects have been mild and transient. The clinical adverse reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg). The clinical adverse reactions listed in Table 2 represent data from Phase II placebo-controlled studies and long-term controlled clinical trials (426 patients given indapamide 2.5 mg or 5 mg).

The reactions are arranged into two groups: 1) a cumulative incidence equal to or greater than 5%; 2) a cumulative incidence less than 5%. Reactions are counted regardless of relation to drug. TABLE 1: Adverse Reactions from Studies of 1.25 mg Incidence ≥ 5% Incidence < 5% 1 BODY AS A WHOLE Headache Infection Pain Back Pain Asthenia Flu Syndrome Abdominal Pain Chest Pain GASTROINTESTINAL SYSTEM Constipation Diarrhea Dyspepsia Nausea METABOLIC SYSTEM Peripheral Edema CENTRAL NERVOUS SYSTEM Dizziness Nervousness Hypertonia RESPIRATORY SYSTEM Rhinitis Cough Pharyngitis Sinusitis SPECIAL SENSES Conjunctivitis 1 OTHER All other clinical adverse reactions occurred at an incidence of < 1%.

Approximately 4% of patients given indapamide 1.25 mg compared to 5% of the patients given placebo discontinued treatment in the trials of up to 8 weeks because of adverse reactions. In controlled clinical trials of 6 to 8 weeks in duration, 20% of patients receiving indapamide 1.25 mg, 61% of patients receiving indapamide 5 mg, and 80% of patients receiving indapamide 10 mg had at least one potassium value below 3.4 mEq/L.

In the indapamide 1.25 mg group, about 40% of those patients who reported hypokalemia as a laboratory adverse event returned to normal serum potassium values without intervention. Hypokalemia with concomitant clinical signs or symptoms occurred in 2% of patients receiving indapamide 1.25 mg. TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5 mg Incidence ≥ 5% Incidence < 5% CENTRAL NERVOUS SYSTEM/NEUROMUSCULAR Headache Dizziness Fatigue, weakness, loss of energy, lethargy, tiredness, or malaise Muscle cramps or spasm, or numbness of the extremities Nervousness, tension, anxiety, irritability, or agitation Lightheadedness Drowsiness Vertigo Insomnia Depression Blurred Vision GASTROINTESTINAL SYSTEM Constipation Nausea Vomiting Diarrhea Gastric irritation Abdominal pain or cramps Anorexia CARDIOVASCULAR SYSTEM Orthostatic hypotension Premature ventricular contractions Irregular heart beat Palpitations GENITOURINARY SYSTEM Frequency of urination Nocturia Polyuria DERMATOLOGIC/HYPERSENSITIVITY Rash Hives Pruritus Vasculitis OTHER Impotence or reduced libido Rhinorrhea Flushing Hyperuricemia Hyperglycemia Hyponatremia Hypochloremia Increase in serum urea nitrogen (BUN) or creatinine Glycosuria Weight loss Dry mouth Tingling of extremities Because most of these data are from long-term studies (up to 40 weeks of treatment), it is probable that many of the adverse experiences reported are due to causes other than the drug.

Approximately 10% of patients given indapamide discontinued treatment in long-term trials because of reactions either related or unrelated to the drug. Hypokalemia with concomitant clinical signs or symptoms occurred in 3% of patients receiving indapamide 2.5 mg q.d. and 7% of patients receiving indapamide 5 mg q.d. In long-term controlled clinical trials comparing the hypokalemic effects of daily doses of indapamide and hydrochlorothiazide, however, 47% of patients receiving indapamide 2.5 mg, 72% of patients receiving indapamide 5 mg, and 44% of patients receiving hydrochlorothiazide 50 mg had at least one potassium value (out of a total of 11 taken during the study) below 3.5 mEq/L.

In the indapamide 2.5 mg group, over 50% of those patients returned to normal serum potassium values without intervention. In clinical trials of 6 to 8 weeks, the mean changes in selected values were as shown in the tables below. Mean Changes from Baseline after 8 Weeks of Treatment - 1.25 mg Serum Electrolytes (mEq/L) Serum Uric Acid (mg/dL) BUN (mg/dL) Potassium Sodium Chloride Indapamide 1.25 mg (n=255 to 257) -0.28 -0.63 -2.60 0.69 1.46 Placebo (n=263 to 266) 0.00 -0.11 -0.21 0.06 0.06 No patients receiving indapamide 1.25 mg experienced hyponatremia considered possibly clinically significant (< 125 mEq/L).

Indapamide had no adverse effects on lipids. Mean Changes from Baseline after 40 Weeks of Treatment - 2.5 mg and 5 mg Serum Electrolytes (mEq/L) Serum Uric Acid (mg/dL) BUN (mg/dL) Potassium Sodium Chloride Indapamide 2.5 mg (n=76) -0.4 -0.6 -3.6 0.7 -0.1 Indapamide 5 mg (n=81) -0.6 -0.7 -5.1 1.1 1.4 The following reactions have been reported with clinical usage of indapamide: jaundice (intrahepatic cholestatic jaundice), hepatitis, pancreatitis, and abnormal liver function tests.

These reactions were reversible with discontinuance of the drug. Also reported are erythema multiforme, Stevens-Johnson Syndrome, bullous eruptions, purpura, photosensitivity, fever, pneumonitis, anaphylactic reactions, agranulocytosis, leukopenia, thrombocytopenia, and aplastic anemia. Other adverse reactions reported with antihypertensive/diuretics are necrotizing angiitis, respiratory distress, sialadenitis, xanthopsia.

Postmarketing Experience Eye Disorders Choroidal effusion, acute myopia, and angle-closure glaucoma (frequency not known). 1 1 Module 2.5 SER-indapamide-choroidal effusion-acute myopia and angle-closure glaucoma-Jul2020. To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse reaction frequency tables (US label) US FDA label
TABLE 1: Adverse Reactions from Studies of 1.25 mg
Incidence ≥ 5%Incidence < 5%1
BODY AS A WHOLE
Headache Infection Pain Back PainAsthenia Flu Syndrome Abdominal Pain Chest Pain
GASTROINTESTINAL SYSTEM
Constipation Diarrhea Dyspepsia Nausea
METABOLIC SYSTEM
Peripheral Edema
CENTRAL NERVOUS SYSTEM
DizzinessNervousness Hypertonia
RESPIRATORY SYSTEM
RhinitisCough Pharyngitis Sinusitis
SPECIAL SENSES
Conjunctivitis
1 OTHER All other clinical adverse reactions occurred at an incidence of < 1%.
TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5 mg
Incidence ≥ 5%Incidence < 5%
CENTRAL NERVOUS SYSTEM/NEUROMUSCULAR
Headache Dizziness Fatigue, weakness, loss of energy, lethargy, tiredness, or malaise Muscle cramps or spasm, or numbness of the extremities Nervousness, tension, anxiety, irritability, or agitationLightheadedness Drowsiness Vertigo Insomnia Depression Blurred Vision
GASTROINTESTINAL SYSTEM
Constipation Nausea Vomiting Diarrhea Gastric irritation Abdominal pain or cramps Anorexia
CARDIOVASCULAR SYSTEM
Orthostatic hypotension Premature ventricular contractions Irregular heart beat Palpitations
GENITOURINARY SYSTEM
Frequency of urination Nocturia Polyuria
DERMATOLOGIC/HYPERSENSITIVITY
Rash Hives Pruritus Vasculitis
OTHER
Impotence or reduced libido Rhinorrhea Flushing Hyperuricemia Hyperglycemia Hyponatremia Hypochloremia Increase in serum urea nitrogen (BUN) or creatinine Glycosuria Weight loss Dry mouth Tingling of extremities
Mean Changes from Baseline after 8 Weeks of Treatment - 1.25 mg
Serum Electrolytes (mEq/L)Serum Uric Acid (mg/dL)BUN (mg/dL)
PotassiumSodiumChloride
Indapamide 1.25 mg (n=255 to 257)-0.28-0.63-2.600.691.46
Placebo (n=263 to 266)0.00-0.11-0.210.060.06
Mean Changes from Baseline after 40 Weeks of Treatment - 2.5 mg and 5 mg
Serum Electrolytes (mEq/L)Serum Uric Acid (mg/dL)BUN (mg/dL)
PotassiumSodiumChloride
Indapamide 2.5 mg (n=76)-0.4-0.6-3.60.7-0.1
Indapamide 5 mg (n=81)-0.6-0.7-5.11.11.4

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects Reproduction studies have been performed in rats, mice and rabbits at doses up to 6,250 times the therapeutic human dose and have revealed no evidence of impaired fertility or harm to the fetus due to indapamide. Postnatal development in rats and mice was unaffected by pretreatment of parent animals during gestation.

There are, however, no adequate and well controlled studies in pregnant women. Moreover, diuretics are known to cross the placental barrier and appear in cord blood. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. There may be hazards associated with this use such as fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The half-life of indapamide in whole blood is approximately 14 hours.

The urinary elimination of 14 C-labeled indapamide and metabolites is biphasic with a terminal half-life of excretion of total radioactivity of 26 hours.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Indapamide is the first of a new class of antihypertensive/diuretics, the indolines. The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours. The oral administration of 5 mg (two 2.5 mg tablets) of indapamide to healthy male subjects produced peak concentrations of approximately 260 ng/mL of the drug in the blood within 2 hours.

A minimum of 70% of a single oral dose is eliminated by the kidneys and an additional 23% by the gastrointestinal tract, probably including the biliary route. The half-life of indapamide in whole blood is approximately 14 hours. Indapamide is preferentially and reversibly taken up by the erythrocytes in the peripheral blood.

The whole blood/plasma ratio is approximately 6:1 at the time of peak concentration and decreases to 3.5:1 at 8 hours. From 71% to 79% of the indapamide in plasma is reversibly bound to plasma proteins. Indapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

The urinary elimination of 14 C-labeled indapamide and metabolites is biphasic with a terminal half-life of excretion of total radioactivity of 26 hours. In a parallel design double-blind, placebo-controlled trial in hypertension, daily doses of indapamide between 1.25 mg and 10 mg produced dose-related antihypertensive effects.

Doses of 5 mg and 10 mg were not distinguishable from each other although each was differentiated from placebo and 1.25 mg indapamide. At daily doses of 1.25 mg, 5 mg and 10 mg, a mean decrease of serum potassium of 0.28, 0.61 and 0.76 mEq/L, respectively, was observed and uric acid increased by about 0.69 mg/100 mL. In other parallel design, dose-ranging clinical trials in hypertension and edema, daily doses of indapamide between 0.5 mg and 5 mg produced dose related effects.

Generally, doses of 2.5 mg and 5 mg were not distinguishable from each other although each was differentiated from placebo and from 0.5 mg or 1 mg indapamide. At daily doses of 2.5 mg and 5 mg a mean decrease of serum potassium of 0.5 and 0.6 mEq/Liter, respectively, was observed and uric acid increased by about 1 mg/100 mL.

At these doses, the effects of indapamide on blood pressure and edema are approximately equal to those obtained with conventional doses of other antihypertensive/diuretics. In hypertensive patients, daily doses of 1.25 mg, 2.5 mg and 5 mg of indapamide have no appreciable cardiac inotropic or chronotropic effect. The drug decreases peripheral resistance with little or no effect on cardiac output, rate or rhythm.

Chronic administration of indapamide to hypertensive patients has little or no effect on glomerular filtration rate or renal plasma flow. Indapamide had an antihypertensive effect in patients with varying degrees of renal impairment, although in general, diuretic effects declined as renal function decreased. In a small number of controlled studies, indapamide taken with other antihypertensive drugs such as hydralazine, propranolol, guanethidine, and methyldopa, appeared to have the additive effect typical of thiazide-type diuretics.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Indapamide
PNF listingOral: 1.5 mg MR tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Indapamide · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 4, September 12, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=deb83f97-6c61-4a09-bed6-18dcf1183405
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .